Multifocals: Careful pre-op preparation minimises explantation

Article

Careful patient selection and precise biometry will all help minimise the risk of later explantation of multifocal IOLs.

Careful patient selection and precise biometry will all help minimise the risk of later explantation of multifocal IOLs, Dr Risto Uusitalo of the Helsinki Eye Clinic said.

"There is a stacking effect, where a number of small errors stack up into a large error. That is why it is vital to get precise biometry, and select appropriate patients," explained Dr Uusitalo.

Exclusion criteria include astigmatism greater than 1.0 D, pre-existing ocular pathology, such as very dense cataract where you can't see the fundus properly, and previous refractive procedure. Physical data is not enough, assessing the psychological profile is also vital.

"A teacher once told me, if your patient has more than three pens in his pocket, be careful. They are typically physicians, architects, engineers and artists. They are perfectionists, they have unrealistic expectations and they are less likely to be happy with loss in vision quality," Dr Uusitalo said.

Similarly, professions that depend on the quality of vision should be excluded too, for example truck drivers.

Dr Uusitalo concluded that multifocal IOLs pose some risks that cannot be ignored, these can, however, be reduced and, overall, the benefits outweigh the risk, for the right patient.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.